WO1999026606A3 - SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS - Google Patents
SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS Download PDFInfo
- Publication number
- WO1999026606A3 WO1999026606A3 PCT/EP1998/007198 EP9807198W WO9926606A3 WO 1999026606 A3 WO1999026606 A3 WO 1999026606A3 EP 9807198 W EP9807198 W EP 9807198W WO 9926606 A3 WO9926606 A3 WO 9926606A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained release
- release formulations
- glucosidase
- inhibitors
- emiglitate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12343/99A AU1234399A (en) | 1997-11-25 | 1998-11-11 | Sustained release formulations comprising alpha-glucosidase-i nhibitors |
JP2000521808A JP2001523704A (en) | 1997-11-25 | 1998-11-11 | Sustained release formulation comprising an α-glucosidase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6669897P | 1997-11-25 | 1997-11-25 | |
US60/066,698 | 1997-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999026606A2 WO1999026606A2 (en) | 1999-06-03 |
WO1999026606A3 true WO1999026606A3 (en) | 1999-08-12 |
Family
ID=22071124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/007198 WO1999026606A2 (en) | 1997-11-25 | 1998-11-11 | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2001523704A (en) |
AR (1) | AR017664A1 (en) |
AU (1) | AU1234399A (en) |
WO (1) | WO1999026606A2 (en) |
ZA (1) | ZA9810710B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1157696E (en) * | 2000-05-24 | 2007-01-31 | Pfizer | Treatment of rumen acidosis with alpha-amylase inhibitors |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
ATE469161T1 (en) | 2002-08-08 | 2010-06-15 | Kissei Pharmaceutical | PYRAZOLE DERIVATIVE, MEDICAL COMPOSITION CONTAINING SAME, MEDICAL USE THEREOF, AND INTERMEDIATE FOR THE PRODUCTION THEREOF |
JP4902348B2 (en) | 2004-03-04 | 2012-03-21 | キッセイ薬品工業株式会社 | Nitrogen-containing fused ring derivative, pharmaceutical composition containing it, and pharmaceutical use thereof |
CN102631332A (en) * | 2012-04-28 | 2012-08-15 | 邹立兴 | Voglibose tablet and preparation method thereof |
CN104013590A (en) * | 2014-05-09 | 2014-09-03 | 万特制药(海南)有限公司 | Acarbose-containing medicinal composition and preparation method thereof |
WO2016001843A1 (en) * | 2014-06-30 | 2016-01-07 | Sun Pharmaceutical Industries Limited | Extended-release gastroretentive tablets of voglibose |
KR101937069B1 (en) * | 2014-12-17 | 2019-04-03 | 엠프로스 파마 악티에볼라그 | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders |
CN110898025A (en) * | 2019-12-12 | 2020-03-24 | 湖北欣泽霏药业有限公司 | Acarbose sustained-release preparation and preparation method thereof |
CN111265489A (en) * | 2020-03-10 | 2020-06-12 | 乐普制药科技有限公司 | Divisible acarbose pellet sustained-release tablet |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0073428A2 (en) * | 1981-09-01 | 1983-03-09 | Bayer Ag | Medicinal preparations for glycoside-hydrolase inhibitors |
EP0194794A2 (en) * | 1985-03-08 | 1986-09-17 | Takeda Chemical Industries, Ltd. | Saccharide digestion inhibiting composition |
EP0364696A2 (en) * | 1988-08-22 | 1990-04-25 | Takeda Chemical Industries, Ltd. | Alpha-glucosidase inhibitor as a calcium absorption promotor |
EP0610854A1 (en) * | 1993-02-10 | 1994-08-17 | Takeda Chemical Industries, Ltd. | Tablets with improved abrasion resistance and method to produce them |
-
1998
- 1998-11-11 WO PCT/EP1998/007198 patent/WO1999026606A2/en not_active Application Discontinuation
- 1998-11-11 AU AU12343/99A patent/AU1234399A/en not_active Abandoned
- 1998-11-11 JP JP2000521808A patent/JP2001523704A/en active Pending
- 1998-11-24 ZA ZA9810710A patent/ZA9810710B/en unknown
- 1998-11-24 AR ARP980105946A patent/AR017664A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0073428A2 (en) * | 1981-09-01 | 1983-03-09 | Bayer Ag | Medicinal preparations for glycoside-hydrolase inhibitors |
EP0194794A2 (en) * | 1985-03-08 | 1986-09-17 | Takeda Chemical Industries, Ltd. | Saccharide digestion inhibiting composition |
EP0364696A2 (en) * | 1988-08-22 | 1990-04-25 | Takeda Chemical Industries, Ltd. | Alpha-glucosidase inhibitor as a calcium absorption promotor |
EP0610854A1 (en) * | 1993-02-10 | 1994-08-17 | Takeda Chemical Industries, Ltd. | Tablets with improved abrasion resistance and method to produce them |
Also Published As
Publication number | Publication date |
---|---|
AR017664A1 (en) | 2001-09-12 |
WO1999026606A2 (en) | 1999-06-03 |
JP2001523704A (en) | 2001-11-27 |
ZA9810710B (en) | 1999-06-14 |
AU1234399A (en) | 1999-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2251453A1 (en) | 5-arylalkyl-substituted pyrazolo(4,3-d)pyrimidine-7-ones | |
WO2001032646A3 (en) | Sulfonamide derivatives | |
PL319605A1 (en) | Novel benzoxazoles | |
AU1690399A (en) | Neovascularization inhibitor containing dienogest as the active ingredient | |
AU3192495A (en) | N,n-disubstituted amic acid derivative | |
AU9254698A (en) | Thickening agents for acidic aqueous compositions | |
NO20002217D0 (en) | Cyclopentane-heptanoic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | |
NO20003150L (en) | Procedure for the preparation of tablets dissolved by chewing | |
AU5313496A (en) | Nodulisporic acid derivatives | |
CA2367724A1 (en) | Packaging system for cosmetic formulations | |
WO1999026606A3 (en) | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS | |
WO2001007049A3 (en) | Ophthalmic composition comprising ketotifen | |
CA2362698A1 (en) | Resorcinol derivatives | |
AU6386801A (en) | System for the release of active ingredients | |
AU7810098A (en) | 9-oxa prostaglandin analogs as ocular hypotensives | |
AU7270798A (en) | Antithrombotic agents | |
AU1025799A (en) | Thickening agents for acidic aqueous compositions | |
FR2799381B1 (en) | SPRAY HEAD, ESPECIALLY FOR FIRE FIGHTING INSTALLATION | |
CA2286296A1 (en) | Inhibitors for urokinase receptor | |
CA2366623A1 (en) | Resorcinol composition | |
CA2214072A1 (en) | Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods | |
CA2270301A1 (en) | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for their preparation | |
ZA974033B (en) | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors. | |
HK1049146A1 (en) | Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23. | |
ZA978406B (en) | Nodulisporic acid derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998955566 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09554153 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998955566 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |